Acta Neuropathologica Communications (May 2018)
A common antigenic motif recognized by naturally occurring human VH5–51/VL4–1 anti-tau antibodies with distinct functionalities
- Adrian Apetri,
- Rosa Crespo,
- Jarek Juraszek,
- Gabriel Pascual,
- Roosmarijn Janson,
- Xueyong Zhu,
- Heng Zhang,
- Elissa Keogh,
- Trevin Holland,
- Jay Wadia,
- Hanneke Verveen,
- Berdien Siregar,
- Michael Mrosek,
- Renske Taggenbrock,
- Jeroenvan Ameijde,
- Hanna Inganäs,
- Margot van Winsen,
- Martin H. Koldijk,
- David Zuijdgeest,
- Marianne Borgers,
- Koen Dockx,
- Esther J. M. Stoop,
- Wenli Yu,
- Els C. Brinkman-van der Linden,
- Kimberley Ummenthum,
- Kristof van Kolen,
- Marc Mercken,
- Stefan Steinbacher,
- Donata de Marco,
- Jeroen J. Hoozemans,
- Ian A. Wilson,
- Wouter Koudstaal,
- Jaap Goudsmit
Affiliations
- Adrian Apetri
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Rosa Crespo
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Jarek Juraszek
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Gabriel Pascual
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Roosmarijn Janson
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Xueyong Zhu
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute
- Heng Zhang
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute
- Elissa Keogh
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Trevin Holland
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Jay Wadia
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Hanneke Verveen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Berdien Siregar
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Michael Mrosek
- Proteros Biostructures GmbH, Bunsenstraße 7a
- Renske Taggenbrock
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Jeroenvan Ameijde
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Hanna Inganäs
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Margot van Winsen
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Martin H. Koldijk
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- David Zuijdgeest
- Janssen Vaccines and Prevention, Janssen Pharmaceutical Companies of Johnson and Johnson
- Marianne Borgers
- Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson
- Koen Dockx
- Molecular and Cellular Pharmacology, Discovery Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson
- Esther J. M. Stoop
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Wenli Yu
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute
- Els C. Brinkman-van der Linden
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Kimberley Ummenthum
- Department of Pathology, Amsterdam Neuroscience, VU University Medical Center
- Kristof van Kolen
- Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson
- Marc Mercken
- Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson
- Stefan Steinbacher
- Proteros Biostructures GmbH, Bunsenstraße 7a
- Donata de Marco
- Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson
- Jeroen J. Hoozemans
- Department of Pathology, Amsterdam Neuroscience, VU University Medical Center
- Ian A. Wilson
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute
- Wouter Koudstaal
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- Jaap Goudsmit
- Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson
- DOI
- https://doi.org/10.1186/s40478-018-0543-z
- Journal volume & issue
-
Vol. 6,
no. 1
pp. 1 – 17
Abstract
Abstract Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer’s Disease (AD). By interrogating IgG+ memory B cells from asymptomatic donors with tau peptides, we have identified two somatically mutated VH5–51/VL4–1 antibodies. One of these, CBTAU-27.1, binds to the aggregation motif in the R3 repeat domain and blocks the aggregation of tau into paired helical filaments (PHFs) by sequestering monomeric tau. The other, CBTAU-28.1, binds to the N-terminal insert region and inhibits the spreading of tau seeds and mediates the uptake of tau aggregates into microglia by binding PHFs. Crystal structures revealed that the combination of VH5–51 and VL4–1 recognizes a common Pro-Xn-Lys motif driven by germline-encoded hotspot interactions while the specificity and thereby functionality of the antibodies are defined by the CDR3 regions. Affinity improvement led to improvement in functionality, identifying their epitopes as new targets for therapy and prevention of AD.
Keywords